TABLE 1.

The body weight and fasting blood glucose level of nondiabetic (normal) and diabetic rats at the end of the study. After 7 days of STZ induction, fasting blood glucose levels were measured (>250 mg/dL defined as a diabetic rat), and this group was designated as the diabetic group (n = 5 each group). Citrate buffer was injected into the nondiabetic group (FBS<150 mg/dL), which was designated as the normal control group. After wounding, the diabetic wounds were treated daily with NSS or the B1 siRNA/Ca-P nanoparticle complex and were compared to the NSS nondiabetic wound.

Rat model	Nondiabetic	Diabetic
		NSS treated	B1 siRNA treated
Body weight (g)	278.0 ± 4.1	193.6 ± 6.9***	191.6 ± 5.8***
Fasting blood glucose (mg/dL)	122.6 ± 8.6	424.4 ± 18.4***	410.8 ± 11.1***

Data are presented as means ± S.E.M. ***p < 0.001 significant difference compared with the nondiabetic group.